recombinant onco-BCG (Instituto Butantan)

N/A

Report date: 2025/03/20 09:39:03
NME

Base Information

Drug Namerecombinant onco-BCG (Instituto Butantan)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunostimulants
TargetsUpdating
Therapy Area/IndicationsUrinary Bladder Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBrazil
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesInstituto Butantan
China Registration ClassN/A

Develop Information

Active CompaniesInstituto Butantan
Inactive CompaniesN/A
Active IndicationsUrinary Bladder Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A